Human sera containing respiratory syncytial (RS) virus-specific antibodies enhance RS virus infection of the U937 macrophage cell line. There was an increase in the number of cells expressing virus antigen when U937 cells were infected with RS virus in the presence of human serum compared to cells infected in the absence of human serum. Human sera enhanced virus yield, as measured by the cell-released infectious virus, by an average of 50-fold compared to virus infection in the absence of human serum. The comparison of the enhancing activities of paired acute and convalescent human sera showed that the titre of enhancing antibody increased in parallel with the titre of RS virus-specific antibody measured by complement fixation and virus neutralization. An RS virus-specific neutralizing monoclonal antibody directed to the virus F protein enhanced virus infection of U937 cells. A non-neutralizing monoclonal antibody directed to the virus nucleoprotein did not enhance virus infection. The possible role of enhancing antibodies in vivo is discussed.
INTRODUCTION
Respiratory syncytial (RS) virus is a major cause of acute respiratory infections in young children. The use of a formalin-inactivated RS virus vaccine predisposed children to severe illness when subsequently infected with RS virus (Kim et al., 1969) . Following immunization, children developed lower neutralizing antibody titres than those of a comparable age who had natural RS virus infections and had not been immunized (Murphy et al., 1986) . Chin et al. (1969) found higher virus shedding and virus isolation rates in vaccinees compared to unvaccinated children when both groups were naturally infected with RS virus. These data led to the speculation that low antibody titres contributed to the severity of the RS virus infections. A possible explanation for these data is antibody-dependent enhancement of virus infection, as proposed by Porterfield (1982) and Halstead (1982) , although no experimental data were presented at that time.
The in vitro enhancement of virus infection of macrophage cell lines by virus-specific antibodies at sub-neutralizing concentrations has been reported for several viruses (reviewed by Halstead, 1982) . The initial stages of virus enhancement require the formation of a virusantibody complex which then attaches, via the Fc portion of the antibody, to the macrophage Fc receptor; this facilitates the entry of the virus as compared to virus infection in the absence of antibody (Gollins & Porterfield, 1984) . The sites of replication of RS virus in the respiratory tract are poorly understood and the role of antibody-dependent enhancement in RS virus pathogenesis remains to be determined. Recently, RS virus has been shown to replicate in vitro in human peripheral blood mononuclear leukocytes (Krilov et al., 1987) . In addition, RS virus antigen has been found in circulating mononuclear leukocytes of infants with RS virus infections (Dumorat et al., 1985) . The present report describes the infection of the U937 human macrophage cell line by RS virus and the occurrence of virus-enhancing antibodies in human sera. ). The cells were maintained in complete RPMI 1640 medium (RPMI 1640 medium containing 100 units/ml penicillin, 100 ktg/ml streptomycin, non-essential amino acids, 1 mM-sodium pyruvate) supplemented with 10~ heat-inactivated foetal bovine serum (IFBS). BS-C-1 cells were maintained in MEM containing I0~ newborn bovine serum.
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The source of the RS-A2 strain of human RS virus has been described previously (Gimenez et al., 1986) . Virus stocks were prepared in BS-C-1 cells.
Source of human sera and monoclonal antibodies (MAbs) . Human serum samples with known complement fixation (CF) antibody titres to RS virus were obtained from the Virus Diagnostic Laboratory, Department of Medical Microbiology, University of Aberdeen. The plaque reduction neutralization titres of the human sera against the RS-A2 strain of RS virus were determined as described by Pringle & Cross (1978) . The murine MAbs 4-15 and 4-18 were prepared in our laboratory and have been described elsewhere (Gimenez et at., 1986 (Gimenez et at., , 1987 .
Antibody-dependent enhancement (ADE) assay. The method used to determine the enhancement of RS virus infection by human serum was modified from that of Peiris & Porterfield (1981) . Serum dilutions 00 -1 to 10 -5) were prepared in complete RPMI 1640 medium supplemented with 5 ~ IFBS (RPMI-IFBS). A portion (0.1 ml) of each dilution was mixed with 0.1 ml (containing approx. 5 × lif t p.f.u.) of RS-A2 virus, previously clarified by centrifugation for 1 min at 11600 g in an MSE microfuge. The virus-serum mixture was incubated for 30 min at 37 °C in an atmosphere of 5~ CO2. The controls contained 0.1 ml of RPMI-IFBS medium instead of human serum, and these are designated as 'no serum' (NS) in the text. A suspension (0-1 ml) of U937 cells (1.6 x 105 to 2.3 × l0 s cells), prepared in RPMI-IFBS medium, was added to the virus-serum mixtures. The cells were incubated for 60 rain at 37 °C, washed three times in RPMI-IFBS and the incubation was continued in fresh RPMI-IFBS. At the times indicated in the text, the titre of the cell-released virus was determined by plaque assay in BS-C-1 cell monolayers (Gimenez et al., 1986) ; virus titres were determined from dishes containing no more than 250 virusspecific foci. All virus titrations were performed in duplicate or triplicate.
Enhancement was calculated as the ratio between the amount of virus released from U937 cells infected with RS virus in the presence of human serum and the amount of virus released from control samples (NS). Enhancement was considered significant at a value of threefold or greater (Peiris & Porterfield, 1981) . The enhancement titre was defined as the highest serum dilution that produced significant enhancement of virus replication. The occurrence of significant enhancement was also determined from the following equation (Halstead et al., 1983) : Xl -xo/~ + Xo ~> 1.96 (P ~< 0.05), where x 1 is the plaque count from U937 cells infected in the presence of human serum and Xo is the plaque count from U937 cells infected in the absence of human serum.
RS virus-infected U937 cells were prepared for immunofluorescence (IF) staining by washing twice with PBS before resuspending in PBS. Cytocentrifuge preparations were made from the cell suspensions, fixed with acetone at -20 °C for 1 min and stained using bovine anti-RS virus and anti-bovine FITC-conjugated sera (Wellcome) (Gimenez et al., 1984) .
RESULTS

Assay conditions for ADE
Our initial experiments assayed for RS virus replication in U937 cells using IF staining of infected cells. When U937 cells were infected with RS virus in the presence of human serum (neutralization titre >i 1/3200) at a dilution of 1 : 1000, 1 ~o of the cells expressed RS virus antigen at 3 days post-infection (p.i.) compared to only 0.04 ~ of cells infected in the absence of human serum. A similar pattern of enhanced infection in the presence of human serum was found when virus replication was assayed by the quantification of cell-released virus, and this method was used in subsequent experiments.
The optimum time for determining the enhancing activity of human sera following RS virus infection was established as follows. U937 cells were infected with RS-A2 virus in the presence of human serum at a dilution of 1:1000; a preliminary experiment showed that this serum dilution had maximum enhancing activity (data not shown). The virus released from these cells and from NS controls was assayed at the times indicated (Fig. 1) . Although RS-A2 virus replicated in U937 cells in both the presence and absence of human serum, higher titres of virus were consistently found in the presence of human serum. The enhancement of this serum reached a maximum value of 34-fold at 43 h p.i. Additional time course experiments showed a similar pattern when virus replication was followed for up to 6 days p.i. (data not shown). Fig. 1 . Replication of RS-A2 virus in U937 cells. U937 ceils were infected with RS-A2 virus (m.o.i. 0-2) which had been pre-incubated with a 1:1000 dilution of human serum (I-]). In parallel, U937 cells were also infected with RS-A2 virus in the absence of human serum (m). The cells were incubated for 1 h at 37 °C before washing with RPMI-IFBS. Samples of the infected cells were then placed into the wells of a 24-well plate (2 x 105 cells/well) and incubated at 37 °C in 2 ml RPMI-IFBS. At the times p.i. indicated, the medium from one well was harvested, and the cell-released virus titres were determined. The entire experiment was carried out in duplicate and the error bars are indicated in the figure. t Enhancement value calculated as the ratio between the amount of virus released from U937 cells infected in the presence of human serum and the amount released from U937 cells infected in the absence of human serum.
Log~ o of final dilution of human serum in the growth medium. § ND, Not done. ADE assays in which the virus-infected cells were grown in media supplemented with the test human serum at sub-neutralizing concentrations were reported by Halstead et al. (1983) . This modification to the ADE assay was investigated for RS virus by including the human sera in the growth medium at dilutions between 10 -3 and 10-v ( t Reciprocal dilution giving 50~ reduction in virus titre. The titre of the acute serum for patient T fell between two dilutions. :~ Enhancement value calculated as the ratio between the amount of virus released from U937 cells infected in the presence of human serum and the amount released from U937 cells infected in the absence of human serum.
§ LOglo human serum dilution used in ADE assay described in Methods.
a dilution of 1 : 1000 for the pre-incubation of the virus and serum. The effect of the human sera was variable depending on the sera and on the dilution used in the growth medium. Based on these data, further ADE assays were carried out without the addition of human sera to the growth medium.
Determination of the enhancing activities of human serum samples
Eight paired human serum samples were compared for ADE ( Table 2 ). The paired sera from patients O, H, P, S and W have been described elsewhere (Gimenez et al., 1987) . Patients M, B and T were aged between 63 and 84 years and had respiratory infections. The paired sera from all of the patients except for T showed at least a fourfold rise in the CF antibody titre to RS virus; the remaining serum pair had only a twofold rise in CF antibody titre. All of the sera enhanced RS virus infection in U937 cells relative to the virus infection in the absence of serum. The enhancement ranged between three-and 112-fold. For all patients, except patient T, there was a 10-to 100-fold difference between the acute and convalescent sera in the serum dilution at which enhancement was maximal. For patient T the acute and convalescent sera showed maximum enhancement at the same dilution. The enhancement titre showed a rise between the acute and convalescent sera, reaching a titre 4 of 10-for patient W and greater than or equal to 10 -5 for the remaining patients.
In the majority of experiments, RS virus-infected U937 ceils formed aggregates by 3 days p.i. (Fig. 2) . The presence of sub-neutralizing concentrations of human sera in the growth medium, such as those used in Table 1 , increased cell aggregation. Uninfected U937 cells incubated in the presence of sub-neutralizing concentrations of human serum did not aggregate, indicating that cell aggregation required virus replication.
ADE by RS virus-specific murine MAbs
The ADE assay was performed using two RS virus-specific MAbs. The antibodies 4-15 and 4-18 have previously been shown to react with the virion surface protein (F) and nucleoprotein (Gimenez et al., 1986 (Gimenez et al., , 1987 .
1" Reciprocal dilution giving 50% reduction in virus titre. :~ The MAb was used at a dilution of 10 -5 in the growth medium. § Enhancement value calculated as the ratio between the amount of virus released from U937 cells infected in the presence of human serum and the amount released from U937 cells infected in the absence of human serum.
[I Log~0 antibody dilution used in ADE assay described in Methods. ¶ ND, Not done.
respectively (Gimenez et al., 1986 (Gimenez et al., , 1987 . Only MAb 4-15 neutralized virus infectivity.
Significant enhancement was found with this MAb in two independent experiments (Table 3) . No significant enhancement was observed with MAb 4-18.
DISCUSSION
The experiments presented showed that RS virus replicated in the U937 macrophage cell line and that the replication was enhanced in the presence of human serum containing low titres of RS virus antibodies. IF staining indicated a 25-fold increase in the number of U937 cells expressing RS virus antigen when infected in the presence, compared to the absence, of human serum; this enhancement is similar in magnitude to that found for reovirus (Burstin et al., 1983) .
Our data suggest that the enhancement effect of the human sera was possibly due to an increase in the number of RS virus-infected cells rather than an increase in virus replication from a constant number of cells. A similar result was reported for yellow fever virus by .
The quantification of the enhancing activity of human sera was most conveniently done by titrating the cell-released RS virus from infected U937 cells. The following two factors which could affect the ADE assay were examined. The inclusion of human sera in the growth medium, as used for dengue virus (Brandt et al., 1982; Halstead et al., 1983) , had a variable effect on the value of the enhancement for RS virus. This was most likely due to the interplay of virus neutralization and enhancement. Since this interaction was variable between sera, further ADE assays were carried out in the absence of human serum in the growth medium. It was determined empirically that at 43 to 48 h p.i. there was maximum enhancement for the human sera tested. RS virus productively infected U937 cells in the absence of human serum, but less efficiently than RS virus that had been pre-incubated with human serum.
Using the conditions of the ADE assay established, the enhancing activities of human sera were determined. In general, the enhancing titre of human sera followed the titre of RS virusspecific antibodies determined by CF and neutralization. A similar pattern was observed when the enhancing titre was compared with the RS virus antibodies analysed by immunoblotting (Gimenez et al., 1987) . This trend was shown for single human serum samples with high titres of RS virus antibodies and with paired serum samples. The latter samples clearly showed a rise in enhancing titre paralleling the rise in complement fixation and neutralizing antibody titre. However, this does not mean that the antibodies responsible for enhancement are necessarily the same as those responsible for CF and neutralization. The paired sera also showed a shift between the acute and convalescent sera in the serum dilution with maximum enhancement. The absolute value for the enhancement for a particular human serum varied when it was used in the ADE assay on different occasions. However, using a value of threefold or greater for the enhancement as being significant, the enhancing activity for that particular human serum was positive on all the occasions it was tested. Furthermore, the serum dilution showing maximum enhancement was also consistent between the tests. A similar variability in virus yield in ADE assays with U937 cells was reported by Schlesinger & Brandriss (1981 b) for yellow fever virus.
From the data obtained with RS virus-specific MAbs and the comparison of the paired human sera, we can conclude that the RS virus-specific antibodies in human serum are responsible for the enhancing activity. Based on the initial studies with the RS virus-specific MAbs, at least one enhancing epitope resided on the virion surface protein, F. It remains to be determined whether enhancing and neutralizing activities can also reside with different antibodies, as found with dengue virus (Brandt et al., 1982; Halstead et al., 1984) . Furthermore, MAbs with different protein specificities have to be examined in order to establish which of the virus proteins, other than the F protein, can induce enhancing antibodies.
It is likely that the mechanism of enhancement of RS virus infection is similar to that proposed for other viruses, involving the macrophage Fc receptor to facilitate internalization of the virus Halstead, 1982) . Cardosa et al. (1986) presented evidence showing that the macrophage complement receptor can also function in ADE assays with West Nile virus. It will be necessary to determine which of the two receptors is involved in RS virus enhancement.
Our experiments show that RS virus infection was enhanced in vitro, but the significance of in vivo enhancement is unknown. It may be pertinent to reassess some of the studies on the antibody-mediated immunity to RS virus. It has been well documented that RS virus infection is severe in infants of less than 6 months of age with low levels of maternal antibodies. Glezen et aL (1981) proposed that there was insufficient maternal antibody present to be protective. However, this could be extended to the possibility that low levels of maternal antibodies, which fail to neutralize RS virus, could actually enhance virus infection. Murphy et al. (1986) showed that children who received a formalin-inactivated RS virus vaccine had high titres of 'nonfunctional' antibodies which essentially had no neutralizing and syncytium-inhibiting activities. The severe infections that these children suffer after vaccination may be due to a severe Arthus reaction caused by the non-functional antibodies (Murphy et al., 1986) . From our data, an additional factor may have been involved. The vaccine may have induced high titres of enhancing antibodies; in this situation the severe pulmonary pathology in vaccinees could have been the result of both an Arthus reaction and enhanced virus replication in macrophages. It would be of interest to examine the sera from these children for RS virus-enhancing antibodies.
